Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide with nearly 1,4 million newly diagnosed patients each year, accounting for 8% of all cancer related deaths.
Highlights
Sentinel lymph node (SLN) mapping with multilevel-sectioning and immunohistochemistry (IHC) or OneStep Nucleic Acid Amplification (OSNA) are considered promising techniques to improve Lymph node (LN) staging in colon cancer
The objective of this study is to investigate the prognostic value of One-Step Nucleic Acid Amplification (OSNA) and IHC in ex vivo detected SLNs of stage I&II (H&E node negative) colon cancer patients
Our study is one of the first published study investigating the prognostic value for disease free survival of OSNA in the long-term follow-up of ex vivo detected SLNs of a small group of stage I&II colon cancer patients, showing no additional prognostic value
Summary
Sentinel lymph node (SLN) mapping with multilevel-sectioning and immunohistochemistry (IHC) or OneStep Nucleic Acid Amplification (OSNA) are considered promising techniques to improve LN staging in colon cancer. Previous studies demonstrated that 20-30% of node negative (stage I&II) patients suffer from disease recurrence within 5 years after surgery [4,5]. This could suggest that current conventional histopathological staging procedures, consisting of one or two sections of Hematoxylin & Eosin (H&E) through each detected LN, may not be precise enough to accurately describe the metastatic load in the resected LNs, possibly leading to undertreatment [6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
